Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US
New PDUFA action date for Brixadi set for 15 December 2021 Lund, Sweden — 26 June 2021 — Camurus (NASDAQ STO: CAMX) announced today that the New Drug Application (NDA) by Camurus’ US licensee Braeburn for Brixadi™ (buprenorphine) extended-release weekly and monthly injection for subcutaneous use for moderate to severe opioid use disorder was accepted for review by the US Food and Drug Administration (FDA). The Prescription Drug User Fee Act (PDUFA) action date is set for 15 December 2021. “We are pleased that the FDA has accepted Braeburn’s updated new drug application for Brixadi. We